Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Endometrial Neoplasms 3Neoplasm Metastasis 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Obesity 1Fallopian Tube Neoplasms 1Endometrial Cancer Recurrent 1Disease 1Carcinosarcoma 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 4liposomal doxorubicin 2Interleukin-12 Subunit p35 2Interleukin-12 2Early Intervention, Educational 2Docetaxel 2veliparib 1tipifarnib 1temsirolimus 1sargramostim 1ixabepilone 1entinostat 1cediranib 1Watchful Waiting 1Vorinostat 1Vinorelbine 1Therapeutics 1Taxes 1TIC10 compound 1Standard of Care 1Sirolimus 1Radiotherapy 1Pyridoxine 1Psychiatric Rehabilitation 1Propranolol 1Practice Guidelines as Topic 1Physical Therapy Modalities 1Pemetrexed 1Paclitaxel 1Mifepristone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms, Male × TIC10 compound × Gynecologic × Clear all
NCT03394027 2022-08-23

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
30 enrolled 15 charts
BreastGynecologic

Neoplasm Metastasis, Endometrial Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡